398 related articles for article (PubMed ID: 1732043)
1. Mutation(s) of the thymidylate synthase gene of human adenocarcinoma cells causes a thymidylate synthase-negative phenotype that can be attenuated by exogenous folates.
Houghton PJ; Rahman A; Will CL; Dolnick BJ; Houghton JA
Cancer Res; 1992 Feb; 52(3):558-65. PubMed ID: 1732043
[TBL] [Abstract][Full Text] [Related]
2. Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts.
Houghton JA; Williams LG; Cheshire PJ; Wainer IW; Jadaud P; Houghton PJ
Cancer Res; 1990 Jul; 50(13):3940-6. PubMed ID: 2354443
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in xenografts of human colon adenocarcinoma.
Houghton JA; Williams LG; Radparvar S; Houghton PJ
Cancer Res; 1988 Jun; 48(11):3062-9. PubMed ID: 3365696
[TBL] [Abstract][Full Text] [Related]
4. Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2'-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft.
Radparvar S; Houghton PJ; Houghton JA
Biochem Pharmacol; 1989 Jan; 38(2):335-42. PubMed ID: 2914018
[TBL] [Abstract][Full Text] [Related]
5. Relationship between dose rate of [6RS]Leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts.
Houghton JA; Williams LG; de Graaf SS; Cheshire PJ; Rodman JH; Maneval DC; Wainer IW; Jadaud P; Houghton PJ
Cancer Res; 1990 Jun; 50(12):3493-502. PubMed ID: 2140289
[TBL] [Abstract][Full Text] [Related]
6. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
7. Role for cytosolic folate-binding proteins in the compartmentation of endogenous tetrahydrofolates and the 5-formyl tetrahydrofolate-mediated enhancement of 5-fluoro-2'-deoxyuridine antitumor activity in vitro.
Matherly LH; Czajkowski CA; Muench SP; Psiakis JT
Cancer Res; 1990 Jun; 50(11):3262-9. PubMed ID: 2139802
[TBL] [Abstract][Full Text] [Related]
8. Effects of diastereoisomers of 5-formyltetrahydrofolate on cellular growth, sensitivity to 5-fluoro-2'-deoxyuridine, and methylenetetrahydrofolate polyglutamate levels in HCT-8 cells.
Zhang ZG; Rustum YM
Cancer Res; 1991 Jul; 51(13):3476-81. PubMed ID: 2054787
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase.
Duch DS; Banks S; Dev IK; Dickerson SH; Ferone R; Heath LS; Humphreys J; Knick V; Pendergast W; Singer S
Cancer Res; 1993 Feb; 53(4):810-8. PubMed ID: 8428362
[TBL] [Abstract][Full Text] [Related]
10. Mutants of human colon adenocarcinoma, selected for thymidylate synthase deficiency.
Houghton PJ; Germain GS; Hazelton BJ; Pennington JW; Houghton JA
Proc Natl Acad Sci U S A; 1989 Feb; 86(4):1377-81. PubMed ID: 2537495
[TBL] [Abstract][Full Text] [Related]
11. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
[TBL] [Abstract][Full Text] [Related]
12. Human lymphoblastoid cells with acquired resistance to C2-desamino-C2-methyl-N10-propargyl-5,8-dideazafolic acid: a novel folate-based thymidylate synthase inhibitor.
O'Connor BM; Jackman AL; Crossley PH; Freemantle SE; Lunec J; Calvert AH
Cancer Res; 1992 Mar; 52(5):1137-43. PubMed ID: 1737372
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of thymidylate synthase purified from a human colon adenocarcinoma.
Radparvar S; Houghton PJ; Houghton JA
Arch Biochem Biophys; 1988 Jan; 260(1):342-50. PubMed ID: 3341747
[TBL] [Abstract][Full Text] [Related]
14. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
15. Development and characterization of a human colon adenocarcinoma xenograft deficient in thymidine salvage.
Houghton PJ; Houghton JA; Germain G; Torrance PM
Cancer Res; 1987 Apr; 47(8):2117-22. PubMed ID: 3829001
[TBL] [Abstract][Full Text] [Related]
16. Binding of 5-fluorodeoxyuridylate to thymidylate synthase in human colon adenocarcinoma xenografts.
Houghton JA; Torrance PM; Radparvar S; Williams LG; Houghton PJ
Eur J Cancer Clin Oncol; 1986 Apr; 22(4):505-10. PubMed ID: 3732354
[TBL] [Abstract][Full Text] [Related]
17. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.
Ren Q; Van Groeningen CJ; Hardcastle A; Aherne GW; Geoffroy F; Allegra CJ; Johnston PG; Grem JL
Oncol Res; 1997; 9(2):77-88. PubMed ID: 9167189
[TBL] [Abstract][Full Text] [Related]
18. Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil.
Berger SH; Hakala MT
Mol Pharmacol; 1984 Mar; 25(2):303-9. PubMed ID: 6608049
[TBL] [Abstract][Full Text] [Related]
19. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
[TBL] [Abstract][Full Text] [Related]
20. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules.
Aschele C; Sobrero A; Faderan MA; Bertino JR
Cancer Res; 1992 Apr; 52(7):1855-64. PubMed ID: 1532346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
